Three novel fluoroquinolones with general structure 1-t-butyl-7-[4-substituted (piperazin-1-yl/piperidin-1-yl)] 6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acids were synthesized and evaluated for antitubercular activity in vitro against M. tuberculosis H 37 Rv in Middlebrook 7H9 broth using sparfloxacin, ciprofloxacin and isoniazid as standards. Test compounds were found to be less potent than sparfloxacin; however, one of the compounds was more potent than ciprofloxacin.
Tuberculosis (TB) is a chronic respiratory disease resulting in 2-3 million deaths every year around the world 1 . The currently available medications show serious side effects like hepatotoxicity (isoniazid), damage to auditory nerve (streptomycin), thrombocytopenic purpura (rifampicin) 2 . The emergence of multidrug resistant TB has further complicated the therapy 3 . Fluoroquinolones, which have broad spectrum antibacterial activity coupled with better pharmacokinetic properties, have been found to have good antimycobacterial activity. E.g.: -sparfloxacin, levofloxacin and moxifloxacin 4, 5 . and pyrrolidines at C-7 of fluoroquinolone nucleus are known to influence the spectrum of antibacterial activity 6, 7 . Hence it is proposed to retain the basic structural features of quinolones essential for exhibiting antibacterial activity and modify the substituents at C-7 position. The present work involves introduction of novel substituents on the piperazine ring present at the 7 position to study their contribution to activity. We also wanted to explore the contribution of substituted piperidine at the 7 position on the fluoroquinolone Title compounds I, II and III were synthesized from 1-t butyl-7-chloro-6-fluoro-4-oxo-1,4-dihydro-quinoline-3 carboxylic acid (1) (Scheme 1). Compound (1) was synthesized as per literature procedure 8 . Condensation of equimolar quantities (0.0026 mol) of (1) with 3-(1 piperazinyl) benzisothiazole (2) / 4-(2,4-difluorobenzoyl) piperidine (3) in presence of anhydrous potassium carbonate in 15 ml of N, N-dimethylformamide (DMF) at 120º for 1.5 h followed by removal of DMF, washing with water and recrystallization from ethanol/DMF gave compounds I and II, respectively.
Similarly condensation of equimolar amounts (0.0026 mol) of (1) and (1-t-butoxycarbonyl-3-t-butyl amino carbonyl) piperazine (4), in presence of anhydrous potassium carbonate in 15ml of DMF at 130° for 2.0 h followed by removal of DMF, washing with water and recrystallization from ethanol-DMF (80:20) gave compound III.
All the reactions were monitored by thin layer chromatography. Melting points were taken on Thermonik melting point apparatus. Infrared spectra were recorded on Jasco FT-IR instrument and H 1 -NMR spectra were recorded on Varian NMR spectrophotometer (300 MHz). Melting points, % yield and spectral data are given in Table 1 . Compound (2) was synthesized according to literature method 9 and compounds (3) and (4) 
